RxDoctor Payments Data

Lindy Chapman, PA

Physician Assistant · Canton, NYNPI 1992375877

Payments from drug & device makers

$4,365in general payments, 2019–2025

Across 225 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$484
  • AbbVie$472
  • GSK$470
  • Lilly USA, LLC$207
  • Corium, LLC$135
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$4,365100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,365 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$15,942
Medicare patients
140
Services billed
255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$48,286
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$15,972
EliquisApixaban14$12,297
XareltoRivaroxaban14$11,593
FarxigaDapagliflozin Propanediol11$8,917
JardianceEmpagliflozin11$8,144
Esomeprazole Magnesium12$2,063
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide22$1,724
Albuterol Sulfate HfaAlbuterol Sulfate40$1,640
Levothyroxine Sodium72$1,368
Nebivolol Hcl21$1,339
Rosuvastatin Calcium31$1,259
Omeprazole75$925
Atorvastatin Calcium85$797
Buspirone Hcl18$529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$484$48,28643 claims
GSKTrelegy Ellipta$470$15,97220 claims
PfizerEliquis$96$12,29714 claims
Johnson & JohnsonXarelto$91$11,59314 claims
AstraZenecaFarxiga$1,255$8,91711 claims
Boehringer IngelheimJardiance$77$8,14411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Canton

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →